Bioengineered Protein Drugs Market Forecast, Trend Analysis & Competition Tracking - Global Market Insights 2020 to 2025

Published on : Jan-2020 | List of Tables : 62 | List of Figures : 80 | No. of Pages : 170 | Report Code : FACT4440MR | Format :

Increasing Adoption of Vaccines to Propel Bioengineered Protein Drugs Market Growth

The quest for bioengineered protein drugs continues to surge among patients, as these are found to have relatively less side-effects and are more effective as compared to other drugs. Sensing the growing demand for bioengineered protein drugs, market players are increasing their investments towards the development of a wide range of products that include therapeutic proteins, vaccines, and monoclonal antibodies.

The sales of therapeutic proteins are projected to offer highest value to the bioengineered protein drugs market, exceeding US$ 150 Bn by 2025. High adoption of these drugs is attributable to their competency to maintain the required protein levels in patients, and aid in the treatment of cancer, anaemia, hepatitis B/C, and haemophilia, among others. Besides this, growing significance of preventive care in the healthcare sector is improving sales prospects for bioengineered protein drugs in vaccine formulations.

A recent report added to the comprehensive repository of Fact.MR highlights the adoption rate of vaccines, which is portended to witness a surge at a CAGR of 8.4% in the bioengineered protein drugs market during the forecast period (2020-2025).

assessment of bioengineered protein drugs market by disease

For detailed insights on market taxonomy, request a sample copy of the report here.

Low Returns on High Investment – A Hindrance to Bioengineered Protein Drugs Market Growth

Rise in the number of FDA approvals for bioengineered protein drugs is encouraging market players to increase investments in research & development activities to diversify their product portfolio. For instance, Eli Lilly and Company invests nearly 23% of its annual revenue, while Biogen spends around 22% of its revenue share, in the pharmaceutical sector. However, increasing penetration of biosimilar products and generic drugs filters out the sales potential of expensive branded bioengineered protein drugs.

Humira is a highly prescribed drug by doctors for the treatment of rheumatoid arthritis, Crohn's disease, ankylosing spondylitis, psoriatic arthritis, chronic plaque psoriasis, and polyarticular arthritis. However, the long-term consumption of this monoclonal antibody is highly unaffordable for most patients, as it lacks reimbursement coverage. According to the AARP Public Policy Institute and the University of Minnesota’s PRIME Institute, the cost of 40 mg Humira injectable pens tripled from 2006 and 2017. Such an exponential increase in the prices of branded drugs is offering generic drugs the ground to thrive, and, in turn, limiting the RoI potential of leading players in the bioengineered protein drugs market.

key regions in bioengineered protein drugs market

For detailed regional analysis, request a sample copy of the report here.

High Cost of Branded Drugs Inadvertently Fuelling Growth of Asia Pacific Bioengineered Protein Drugs Market

High cost associated with branded drugs is hampering the growth of leading players, who are based in developed regions such as North America and Europe. However, players operating in Asia Pacific are taking a cue and investing in the development of biosimilar and generic drugs that cost merely 20% of branded drugs. This is limiting the penetration of branded drugs in Asia Pacific and leading to a surge in the popularity of generic ones, which is increasing revenue potential of the bioengineered protein drugs market in this region.

According to the National Health Commission, over 2,000 people died of infectious diseases such as cholera and plague in China, in August 2019. Such an alarming death rate is encouraging the adoption of therapeutics, especially in densely populated countries such as China and India. Also, a huge geriatric population base in Japan seeking cure for arthritis is further strengthening the position of Asia Pacific in the global bioengineered protein drugs market.

Bioengineered Protein Drugs Market – Scope of the Report

The study on the bioengineered protein drugs market is an exclusive report published by Fact.MR, which brings to the fore crucial parameters that are driving the growth of the market. This exclusive study provides incisive insights regarding recent developments in the bioengineered protein drugs market, by analysing the historical data for the period of 2015-2019, with 2020-2025 considered as the forecast period.

Evaluation of the bioengineered protein drugs market’s revenue has been carried out in terms of value (US$ Mn). This research provides information into the key trends that are potential enough to influence the growth of the bioengineered protein drugs market. Besides this, the study also includes several macroeconomic and microeconomic growth indicators complementing the growth of the bioengineered protein drugs market during the forecast period. This detailed study provides information into key dynamics, and their influence on the bioengineered protein drugs market during the forecast period.

The report also provides information about the key challenges and threats that could deter the growth potential of players in the bioengineered protein drugs market. The study unveils profitable opportunities for manufacturers, which they can adopt to strengthen their position in the global bioengineered protein drugs market. With a view of aiding stakeholders in the bioengineered protein drugs market, the study comprises a detailed section on the competition analysis.

This exclusive study offers a dashboard view of the bioengineered protein drugs market, with detailed information about market players, based on overall revenue, key developments, and their market presence. Additionally, key strategies of players in the bioengineered protein drugs market have also been included in this comprehensive study.

Bioengineered Protein Drugs Market – Assessment of Key Segments

Authors of this comprehensive study have classified the market into key segments for an in-depth study of the bioengineered protein drugs market. Categorisation of the bioengineered protein drugs market is based on drug type, disease, end user, and region. This detailed study also offers information about the incremental opportunity present in the bioengineered protein drugs market during the forecast period. Key segments considered while studying the bioengineered protein drugs market include:

Drug Type

Disease

End User

Region

Therapeutic Proteins

Cancer

Pharmaceutical and Biotechnology Companies

North America

Monoclonal Antibodies

Diabetes

CROs Research Institutes

Europe

Vaccines

Autoimmune Disorder

 

Asia Pacific

 

Infectious Diseases

 

Latin America

 

Haematopoiesis

 

Middle East & Africa

 

CVD

 

 

 

Neurodegenerative Diseases

 

 

 

Others

 

 

Revenue of the bioengineered protein drugs market has been evaluated in terms of US$ Mn for the period of 2020 to 2025. In addition to this, compound annual growth rate has been calculated for all key segments for the forecast period of 2020-2025, considering 2019 as the base year.

Authors of this exclusive study on the bioengineered protein drugs market have analysed key players, based on their financials, products, and strategies, in order to provide key detailed information into the competitive landscape. Key players operating in the bioengineered protein drugs market include Abbott Laboratories, Sanofi, Amgen Inc., Reliance Life Sciences Pvt. Ltd., Bayer AG, ProBioGen AG, Bayer AG, Panacea Biotec, Biocon Ltd., Novartis AG, Dr. Reddy’s Laboratories Ltd., Merck & Co., Inc., Eli Lily and Company, Johnson & Johnson (Janssen), F.Hoffmann-La Roche Ltd., GlaxoSmithKline PLC, and Fresenius Kabi.

Bioengineered Protein Drugs Market – Research Methodology

The primary objective of this exclusive study on the bioengineered protein drugs market is to offer precise estimates and forecasts of the market in terms of value (US$ Mn) for the period of 2020-2025. The secondary objective includes analysis of key market segments exhibiting significant growth rates, leading strategies adopted by players in the bioengineered protein drugs market, and the adoption rate of bioengineered protein drugs in key regions across the world.

1 Preface

    1.1 Market Definition and Scope

    1.2 Market Segmentation

    1.3 Key Research Objectives

    1.4 Research Highlights

2 Assumptions and Research Methodology

3 Executive Summary: Global Bioengineered Protein Drugs Market

4 Market Overview

    4.1 Introduction

        4.1.1 Product Overview

        4.1.2 Industry Evolution / Developments

        4.1.3 Key Market Indicators

    4.2 Market Dynamics 

        4.2.1 Drivers

        4.2.2 Restraints

        4.2.3 Opportunity

    4.3 Market Revenue Projections

    4.4 Porter’s Five Force Analysis

    4.5 Value Chain Analysis

    4.6 Market Outlook

5 Global Bioengineered Protein Drugs Market Analysis and Forecasts, by Drug Type

    5.1 Key Findings / Developments

    5.2 Introduction & Definition

    5.3 Market Value Forecast by Drug Type, 2020–2025

        5.3.1 Monoclonal Antibody

            5.3.1.1 Humira

            5.3.1.2 Rituxan

            5.3.1.3 Avastin

            5.3.1.4 Herceptin

            5.3.1.5 Remicade

            5.3.1.6 Lucentis

            5.3.1.7 Enbrel 

            5.3.1.8 Synazis

            5.3.1.9 others

        5.3.2 Therapeutic Proteins Market By Type 

            5.3.2.1 Hormones

            5.3.2.2 Cytokines

                5.3.2.2.1 Neupogen

                5.3.2.2.2 Neulasta

                5.3.2.2.3 Interferon Alpha

                5.3.2.2.4 Erythropoietin Alpha

                5.3.2.2.5 Interleukin

                5.3.2.2.6 Others

            5.3.2.3 Blood Factor

            5.3.2.4 Enzyme Therapy

                5.3.2.4.1 Systemic Enzyme Therapy

                5.3.2.4.2 Digestive Enzyme Therapy

            5.3.2.5 Thrombolytics

                5.3.2.5.1 tPA

                5.3.2.5.2 Streptokinase

                5.3.2.5.3 Urokinase

            5.3.2.6 Vaccines

    5.4 Key Trends

    5.5 Market Attractiveness by Drug Type

6 Global Bioengineered Protein Drugs Market Analysis and Forecasts, by Disease

    6.1 Key Findings / Developments

    6.2 Introduction & Definition

    6.3 Market Value Forecast by Disease, 2020–2025

        6.3.1 Cancer

        6.3.2 Diabetes

        6.3.3 Autoimmune Disorder

        6.3.4 Infectious Disease

        6.3.5 Hematopoiesis

        6.3.6 CVD

        6.3.7 Neurodegenerative

        6.3.8 Others

    6.4 key Trends

    6.5 Market Attractiveness by Disease

7 Global Bioengineered Protein Drugs Market Analysis and Forecasts, by End-user

    7.1 Key Findings / Developments

    7.2 Introduction & Definition

    7.3 Market Value Forecast by End-user, 2020–2025

        7.3.1 Pharma and Biotech Companies

        7.3.2 CROs

        7.3.3 Research Institutes

    7.4 Key Trends

    7.5 Market Attractiveness by End-user

8 Global Bioengineered Protein Drugs Market Analysis and Forecasts, by Region

    8.1 Policies and Regulations

    8.2 Market Value Forecast by Region

        8.2.1 North America 

        8.2.2 Europe 

        8.2.3 Asia Pacific 

        8.2.4 Latin America  

        8.2.5 Middle East & Africa 

    8.3 Market Attractiveness by Region

9 North America Bioengineered Protein Drugs Market Analysis and Forecasts

    9.1 Market Value Forecast by Country, 2020–2025

        9.1.1 U.S.

        9.1.2 Canada

    9.2 Market Value Forecast by Drug Type, 2020–2025

    9.3 Market Value Forecast by Disease, 2020–2025

    9.4 Market Value Forecast by End - User, 2020–2025

    9.5 Market Attractiveness Analysis 

        9.5.1 By Country

        9.5.2 By Drug Type 

        9.5.3 By Disease 

        9.5.4 By End-user

10 Europe Bioengineered Protein Drugs Market Analysis and Forecasts

    10.1 Market Value Forecast by Country, 2020–2025

        10.1.1  Germany

        10.1.2  Italy 

        10.1.3  France 

        10.1.4  U.K.

        10.1.5  Spain

        10.1.6  Rest of Europe 

    10.2 Market Value Forecast by Drug Type, 2020–2025

    10.3 Market Value Forecast by Disease, 2020–2025

    10.4 Market Value Forecast by End-user, 2020–2025

    10.5 Market Attractiveness Analysis 

        10.5.1  By Country

        10.5.2  By Drug Type 

        10.5.3  By Disease 

        10.5.4  By End-user

11 Asia Pacific Bioengineered Protein Drugs Market Analysis and Forecasts

    11.1 Market Value Forecast by Country, 2020–2025

        11.1.1  Japan

        11.1.2  China 

        11.1.3  India

        11.1.4  Rest of APAC

    11.2 Market Value Forecast by Drug Type, 2020–2025

    11.3 Market Value Forecast by Disease, 2020–2025

    11.4 Market Value Forecast by End-user, 2020–2025

    11.5 Market Attractiveness Analysis 

        11.5.1  By Country

        11.5.2  By Drug Type 

        11.5.3  By Disease

        11.5.4  By End-user

12 Latin America Bioengineered Protein Drugs Market Analysis and Forecasts

    12.1 Market Value Forecast by Country, 2020–2025

        12.1.1  Brazil

        12.1.2  Mexico

        12.1.3  Rest of LATAM 

    12.2 Market Value Forecast by Drug Type, 2020–2025

    12.3 Market Value Forecast by Disease, 2020–2025

    12.4 Market Value Forecast by End-user, 2020–2025

    12.5 Market Attractiveness Analysis 

        12.5.1  By Country

        12.5.2  By Drug Type 

        12.5.3  By Disease 

        12.5.4  By End-user

13 Middle East & Africa Bioengineered Protein Drugs Market Analysis and Forecasts

    13.1 Market Value Forecast by Country, 2020–2025

        13.1.1  South Africa

        13.1.2  Saudi Arabia

        13.1.3  Rest of MEA 

    13.2 Market Value Forecast by Drug Type, 2020–2025

    13.3 Market Value Forecast by Disease, 2020–2025

    13.4 Market Value Forecast by End-user, 2020–2025

    13.5 Market Attractiveness Analysis 

        13.5.1  By Country

        13.5.2  By Drug Type 

        13.5.3  By Disease

        13.5.4  By End-user

14 Competitive Landscape

    14.1 Market Share Analysis by Company 2019

    14.2  Company Profiles 

        14.2.1 Abbott Laboratories

            14.2.1.1 Company Details

            14.2.1.2 Company Description

            14.2.1.3 Business Overview

            14.2.1.4 SWOT Analysis

            14.2.1.5 Financial Analysis

            14.2.1.6 Strategic Overview

        14.2.2  Amgen Inc. 

            14.2.2.1 Company Details

            14.2.2.2 Company Description

            14.2.2.3 Business Overview

            14.2.2.4 SWOT Analysis

            14.2.2.5 Financial Analysis

            14.2.2.6 Strategic Overview

        14.2.3  Bayer AG

            14.2.3.1 Company Details

            14.2.3.2 Company Description

            14.2.3.3 Business Overview

            14.2.3.4 SWOT Analysis

            14.2.3.5 Financial Analysis

            14.2.3.6 Strategic Overview

        14.2.4  Biocon Ltd.

            14.2.4.1 Company Details

            14.2.4.2 Company Description

            14.2.4.3 Business Overview

            14.2.4.4 SWOT Analysis

            14.2.4.5 Financial Analysis

            14.2.4.6 Strategic Overview

        14.2.5  Dr. Reddy’s Laboratories  

            14.2.5.1 Company Details

            14.2.5.2 Company Description

            14.2.5.3 Business Overview

            14.2.5.4 SWOT Analysis

            14.2.5.5 Financial Analysis

            14.2.5.6 Strategic Overview

        14.2.6  Eli Lilly and Comapny 

            14.2.6.1 Company Details

            14.2.6.2 Company Description

            14.2.6.3 Business Overview

            14.2.6.4 SWOT Analysis

            14.2.6.5 Financial Analysis

            14.2.6.6 Strategic Overview

        14.2.7  F. Hoffmann – La Roche Ltd.

            14.2.7.1 Company Details

            14.2.7.2 Company Description

            14.2.7.3 Business Overview

            14.2.7.4 SWOT Analysis

            14.2.7.5 Financial Analysis

            14.2.7.6 Strategic Overview

        14.2.8  Fresenius kabi

            14.2.8.1 Company Details

            14.2.8.2 Company Description

            14.2.8.3 Business Overview

            14.2.8.4 SWOT Analysis

            14.2.8.5 Financial Analysis

            14.2.8.6 Strategic Overview

        14.2.9  GlaxoSmithKline plc

            14.2.9.1 Company Details

            14.2.9.2 Company Description

            14.2.9.3 Business Overview

            14.2.9.4 SWOT Analysis

            14.2.9.5 Financial Analysis

            14.2.9.6 Strategic Overview

        14.2.10 Johnson & Johnson (Janseen)

            14.2.10.1 Company Details

            14.2.10.2 Company Description

            14.2.10.3 Business Overview

            14.2.10.4 SWOT Analysis

            14.2.10.5 Financial Analysis

            14.2.10.6 Strategic Overview

        14.2.11 Merck & Co., Inc.

            14.2.11.1 Company Details

            14.2.11.2 Company Description

            14.2.11.3 Business Overview

            14.2.11.4 SWOT Analysis

            14.2.11.5 Financial Analysis

            14.2.11.6 Strategic Overview

        14.2.12  Novartis AG

            14.2.12.1 Company Details

            14.2.12.2 Company Description

            14.2.12.3 Business Overview

            14.2.12.4 SWOT Analysis

            14.2.12.5 Financial Analysis

            14.2.12.6 Strategic Overview

        14.2.13 Panacea Biotec

            14.2.13.1 Company Details

            14.2.13.2 Company Description

            14.2.13.3 Business Overview

            14.2.13.4 SWOT Analysis

            14.2.13.5 Financial Analysis

            14.2.13.6 Strategic Overview

        14.2.14 ProBioGen AG

            14.2.14.1 Company Details

            14.2.14.2 Company Description

            14.2.14.3 Business Overview

            14.2.14.4 SWOT Analysis

            14.2.14.5 Financial Analysis

            14.2.14.6 Strategic Overview

        14.2.15 Reliance Life Science Pvt. Ltd.

            14.2.15.1 Company Details

            14.2.15.2 Company Description

            14.2.15.3 Business Overview

            14.2.15.4 SWOT Analysis

            14.2.15.5 Financial Analysis

            14.2.15.6 Strategic Overview

        14.2.16 Sanofi

            14.2.16.1 Company Details

            14.2.16.2 Company Description

            14.2.16.3 Business Overview

            14.2.16.4 SWOT Analysis

            14.2.16.5 Financial Analysis

            14.2.16.6 Strategic Overview

Fact.MR offers custom research services that help clients to get specific research solutions

We are committed towards customer satisfaction and quality service.


Our Clients

Malaysian Cocoa Board
Dunlop International Europe Ltd
Roland Berger
Superior Essex
Commscope
Deloitte

Fact.MR in Media

Bioengineered Protein Drugs Market Forecast, Trend Analysis & Competition Tracking - Global Market Insights 2020 to 2025